stockrowExelixis, Inc.
EXEL Healthcare Biotechnology
Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +22.2%
- Free cash flow
- −4.83%
Quarter to September 2026, against a year earlier
Follow EXEL
Alert me
Exelixis, Inc. (EXEL) Operating margin
Exelixis, Inc.'s operating margin over the twelve months to 30 September 2026 was 40.2%, up 2.6 percentage points from fiscal 2025 (37.6%). Over the past ten years it has ranged from −326.7% (fiscal 2015) to 51.4% (fiscal 2018); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Operating margin, annual
Embed this chart
Annual newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| FY2025 | 37.6% | 9.71 |
| FY2024 | 27.9% | 18.54 |
| FY2023 | 9.34% | (3.17) |
| FY2022 | 12.5% | (7.47) |
| FY2021 | 20.0% | 8.84 |
| FY2020 | 11.1% | (27.04) |
| FY2019 | 38.2% | (13.22) |
| FY2018 | 51.4% | 14.73 |
| FY2017 | 36.7% | 51.36 |
| FY2016 | −14.7% | 311.96 |
Quarterly newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| Sep 2026 | 40.8% | 1.24 |
| Jun 2026 | 39.5% | (1.64) |
| Mar 2026 | 41.2% | 1.86 |
| Dec 2025 | 39.3% | (0.28) |
| 43 more quarters | Free account |
Against its own ten years
Operating margin against peers
| Company | Operating margin |
|---|---|
| EXEL Exelixis, Inc. | 40.2% |
| HALO Halozyme Therapeutics, Inc. compare | 37.4% |
| ASND Ascendis Pharma A/S compare | 24.8% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 19.5% |
| JAZZ Jazz Pharmaceuticals PLC compare | 9.03% |
| SMMT Summit Therapeutics PLC compare | 0.00% |
| INSM Insmed, Inc. compare | −37.1% |
| BBIO BridgeBio Pharma, Inc. compare | −38.5% |
| BNTX BioNTech SE Sponsored ADR compare | −79.0% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Operating margin is
EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.
EBIT ÷ Revenue
More on EXEL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement